These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26419509)

  • 21. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
    Cao Y; Luetkens T; Kobold S; Hildebrandt Y; Gordic M; Lajmi N; Meyer S; Bartels K; Zander AR; Bokemeyer C; Kröger N; Atanackovic D
    Exp Hematol; 2010 Oct; 38(10):860-7. PubMed ID: 20619313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type.
    Auziņa D; Beinaroviča I; Janicka-Kupra B; Lejniece S; Lejnieks A; Groma V
    Exp Oncol; 2020 Dec; 42(4):285-288. PubMed ID: 33355872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
    Corso A; Arcaini L; Mangiacavalli S; Astori C; Orlandi E; Lorenzi A; Passamonti F; Klersy C; Pascutto C; Canevari-Sciorati A; Lazzarino M
    Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma.
    Shin D; Kim MJ; Chun S; Kim D; Lee C; Ahn KS; Jung E; Kim D; Lee BC; Hwang D; Kim Y; Yoon SS
    Haematologica; 2024 Jul; 109(7):2207-2218. PubMed ID: 38205555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A role for IL-34 in osteolytic disease of multiple myeloma.
    Baghdadi M; Ishikawa K; Nakanishi S; Murata T; Umeyama Y; Kobayashi T; Kameda Y; Endo H; Wada H; Bogen B; Yamamoto S; Yamaguchi K; Kasahara I; Iwasaki H; Takahata M; Ibata M; Takahashi S; Goto H; Teshima T; Seino KI
    Blood Adv; 2019 Feb; 3(4):541-551. PubMed ID: 30782613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.
    Giuliani N; Rizzoli V
    Leuk Lymphoma; 2007 Dec; 48(12):2323-9. PubMed ID: 18067006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
    Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
    Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRAIL produced from multiple myeloma cells is associated with osteolytic markers.
    Kawano Y; Ueno S; Abe M; Kikukawa Y; Yuki H; Iyama K; Okuno Y; Mitsuya H; Hata H
    Oncol Rep; 2012 Jan; 27(1):39-44. PubMed ID: 21993926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging.
    Evangelista L; Panunzio A; Polverosi R; Ferretti A; Chondrogiannis S; Pomerri F; Rubello D; Muzzio PC
    Biomed Pharmacother; 2012 Sep; 66(6):448-53. PubMed ID: 22902054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.
    Xu L; Mohammad KS; Wu H; Crean C; Poteat B; Cheng Y; Cardoso AA; Machal C; Hanenberg H; Abonour R; Kacena MA; Chirgwin J; Suvannasankha A; Srour EF
    Cancer Res; 2016 Dec; 76(23):6901-6910. PubMed ID: 27634757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
    Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA
    Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The value of chest computerized tomography in evaluation of bone disease and clinical prognosis of multiple myeloma].
    Tang W; Da Y; Lin Q; Li H; Gao X; Zhou D; Zhuang J
    Zhonghua Nei Ke Za Zhi; 2015 Aug; 54(8):711-5. PubMed ID: 26674628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review].
    Bao L; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):442-6. PubMed ID: 18426683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.